Phase 1 N=32 Cefdinir Capsules 300 mg, Fasting
Healthy
Primary: Cmax (Maximum Observed Concentration) — 2995.84; 3063.65 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 Cefdinir for Oral Suspension 250 mg/5mL, Fasting
Healthy
Primary: Cmax (Maximum Observed Concentration) — 2638.063; 2557.122 ng/mL
Phase 1 N=40 Mycophenolate Mofetil Tablets Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 11.0939; 11.1715 µg/mL
Phase 1 N=32 Cefdinir Capsules 300 mg, Non-fasting
Healthy
Primary: Cmax (Maximum Observed Concentration) — 2081.37; 2045.43 ng/mL
Phase 1 N=32 Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting
Healthy
Primary: Cmax (Maximum Observed Concentration) — 1477.573; 1484.677 ng/mL
Phase 1 N=32 Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 24.33; 23.62 ng/mL
Phase 1 N=24 Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions
Healthy
Primary: Cmax - Maximum Observed Concentration — 2936.10; 2955.65 ng/mL
Phase 1 N=24 Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline
Pharmacokinetics
Primary: Maximum Plasma Concentration(Cmax) — 9.58; 6.63; 9.81; 7.47 ug/mL
Phase 1 N=18 Comparison Bioavailability Study of Quinine Sulfate in Chocolate Pudding
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) — 3291.411; 3439.867 ng per mL
Phase 1 N=24 Drug-Drug Interaction Study of Qualaquin and Midazolam
Healthy
Primary: Maximum Serum Concentration (Cmax) — 12.0435; 4.6907; 4432.4089; 12.5585 ng/ml
Phase 1 N=33 Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)
Osteoarthritis, Knee
Primary: Change in Average Pain Intensities Measured From the Pre-Treatment Walk (Baseline) at 3 Post-Treatment Walks — 0.24; 0.18; 0.18 Units on a Scale — p=0.743
Phase 1 N=140 Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.
Healthy
Primary: Bioequivalence Based on Rmax — 73.96; 73.99 ng/mL
Phase 1 N=101 Cardiac Home Education and Support Trial (CHEST): A Pilot Study
Coronary Artery Disease
Primary: Health-related Quality of Life (SF-36v2-acute Form) — 72.6; 77.0; 60.4; 65.5 units on a scale — p=p<0.20
Phase 1 N=26 A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions
Healthy
Primary: AUC(0-t) — 5181; 5010 ng.h/mL
Phase 1 N=27 A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers
Healthy
Primary: AUC(0-t) — 2064; 4332; 6568 ng.h/mL